Lv3
295 积分 2021-06-21 加入
Evaluation of the post-marketing safety of eculizumab from 2007 to 2025: A real-world pharmacovigilance study and signal analysis based on the FAERS database
2天前
已完结
Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and meta‑analysis
2天前
已完结
Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis
7天前
已完结
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
8天前
已完结
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
8天前
已完结
Risk factors of death or chronic renal replacement therapy requirements in patients with thrombotic microangiopathies without ADAMTS-13 deficiency
20天前
已完结
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
23天前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
23天前
已完结
A cross-sectional, population-based survey of U.S. adults with symptoms of chronic rhinosinusitis
28天前
已完结
Pioneering a paradigm shift in asthma management: remission as a treatment goal
28天前
已完结
皖公网安备34019202002308
